At 5.7% CAGR, Europe Transient Protein Expression Market is Projected to be Worth US$ 386.23 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Europe transient protein expression market was valued at US$ 247.78 million in 2023 and is expected to reach US$ 386.23 million by 2031, registering a CAGR of 5.7% from 2023 to 2031. Surging popularity of precision medicine and increasing applications of protein expression systems are among the critical factors attributed to drive the Europe transient protein expression market growth.

With advancements in medical technologies, the use of molecular biology techniques has increased significantly in the development of various therapeutic or treatment modalities. Genomic transcriptomic information facilitates the discovery of biomarkers that find applications in monitoring diseases and predicting their risks, serving as a key principle in different therapeutic modalities. The use of personalized or precision medicines has surged dramatically due to the availability of vast information on genetic variations existing among people. For instance, mRNA-mediated therapy is characterized by decreased immunogenicity, superior translation efficacy, enhanced stability, pharmaceutical safety, and transient protein expression, and only the modified mRNA is utilized for therapeutic application instead of incorporating the entire host genome.

Pharmaceutical and biotechnology industries have developed various innovative techniques to treat cancer and neurodegenerative diseases. The transient gene expression technique has aided in significant progress in research related to neurotrauma and neurodegenerative diseases, which has resulted in the introduction of precision medicines for these conditions. Technological advancements in epigenetics, genetics, and proteomics are also supporting the development of therapeutics for the treatment of various genetic and rare genetic diseases caused by single- and multiple-cell disorders.

In addition, IC PerMed is a voluntary, EU Member State-led collaboration between funders of health research, research policymakers, and health policymakers. They have recently come together to set up an initiative called the International Consortium for Personalized Medicine, or “IC PerMed. An executive committee of representatives from each participating organization steers it. Thus, the continuous research and development activities and growing government initiatives to support precision medicine boost the adoption of transient protein expression techniques.

On the contrary, high cost of products hampers the growth of Europe transient protein expression market.

Based on product type, the Europe transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held 35.6% market share in 2023, amassing US$ 88.18 million. It is projected to garner US$ 139.71 million by 2031 to register 5.9% CAGR during 2023–2031.

In terms of application, the Europe transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held 33.4% share of Europe transient protein expression market in 2023, amassing US$ 82.66 million. It is anticipated to garner US$ 137.36 million by 2031 to expand at 6.6% CAGR during 2023–2031.

Based on end user, the Europe transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held 55.4% share of Europe transient protein expression market in 2023, amassing US$ 137.26 million. It is anticipated to garner US$ 219.83 million by 2031 to expand at 6.1% CAGR during 2023–2031.

By country, the Europe transient protein expression market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.5% share of Europe transient protein expression market in 2023. It was assessed at US$ 65.67 million in 2023 and is likely to hit US$ 103.75 million by 2031, registering a CAGR of 5.9% during 2023–2031.

Key players operating in the Europe transient protein expression market are Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com